Community pharmacist intervention in depressed primary care patients (PRODEFAR study): randomized controlled trial protocol

scientific article published on 5 August 2009

Community pharmacist intervention in depressed primary care patients (PRODEFAR study): randomized controlled trial protocol is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1037710076
P356DOI10.1186/1471-2458-9-284
P932PMC publication ID2731750
P698PubMed publication ID19656386
P5875ResearchGate publication ID26718574

P50authorMaria Rubio-ValeraQ43088190
Antoni Serrano-BlancoQ43088197
Marian A. MarchQ71977022
M T Peñarrubia MaríaQ73857122
P2093author name stringMarian March Pujol
Pere Travé
Mar Ruiz
P2860cites workProjections of global mortality and burden of disease from 2002 to 2030Q21144688
Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) projectQ22242341
Prevalence, Severity, and Unmet Need for Treatment of Mental Disorders in the World Health Organization World Mental Health SurveysQ22252996
The PHQ-9: validity of a brief depression severity measureQ24550620
EuroQol--a new facility for the measurement of health-related quality of lifeQ29547873
The revised CONSORT statement for reporting randomized trials: explanation and elaborationQ29618913
Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health QuestionnaireQ33777234
Treatment non-adherence in affective disorders.Q34592227
Sensitivity of patient outcomes to pharmacist interventions. Part I: systematic review and meta-analysis in diabetes managementQ36915765
Sensitivity of patient outcomes to pharmacist interventions. Part II: Systematic review and meta-analysis in hypertension managementQ36966475
Epidemiology of major depressive episode in a southern European country: results from the ESEMeD-Spain projectQ37129559
Concurrent and predictive validity of a self-reported measure of medication adherenceQ39512844
Cost of depression in EuropeQ40284204
Development and validation of a Spanish language patient satisfaction questionnaire with drug dispensingQ42632237
Validation and utility of the patient health questionnaire in diagnosing mental disorders in 1003 general hospital Spanish inpatientsQ43648407
Prevalence of mental disorders in primary care: results from the diagnosis and treatment of mental disorders in primary care study (DASMAP).Q44390153
Impact of a collaborative pharmacy practice model on the treatment of depression in primary care.Q46493733
Patient outcomes following an intervention involving community pharmacists in the management of depression.Q51775849
Adequacy of antidepressant treatment in Spanish primary care: a naturalistic six-month follow-up study.Q51895170
Disability and quality of life impact of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project.Q51940991
Randomized trial of pharmacist interventions to improve depression care and outcomes in primary care.Q51942571
Using the EuroQoI 5-D in the Catalan general population: feasibility and construct validity.Q53576646
Cost Effectiveness of a Pharmacy-Based Coaching Programme to Improve Adherence to AntidepressantsQ57829480
The impact of a pharmacist intervention on 6-month outcomes in depressed primary care patientsQ58723304
A Pharmacy-Based Coaching Program to Improve Adherence to Antidepressant Treatment Among Primary Care PatientsQ60472725
The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patientsQ69903875
[The Spanish version of EuroQol: a description and its applications. European Quality of Life scale]Q73319178
[One year prevalence of mental disorders comorbidity and associated socio-demographic risk factors in the general population of Spain. Results of the ESEMeD-Spain study]Q80672918
[The impact of mood and anxiety disorders, and physical chronic conditions in the quality of life of general population of Spain. Results of the ESEMeD-Spain study]Q80672923
Improving patient feedback about and outcomes with antidepressant treatment: a study in eight community pharmaciesQ82787843
P275copyright licenseCreative Commons Attribution 2.0 GenericQ19125117
P6216copyright statuscopyrightedQ50423863
P407language of work or nameEnglishQ1860
P304page(s)284
P577publication date2009-08-05
P1433published inBMC Public HealthQ15767009
P1476titleCommunity pharmacist intervention in depressed primary care patients (PRODEFAR study): randomized controlled trial protocol
P478volume9

Reverse relations

cites work (P2860)
Q34947318Cost-effectiveness of a community pharmacist intervention in patients with depression: a randomized controlled trial (PRODEFAR Study).
Q34329474Factors affecting collaboration between general practitioners and community pharmacists: a qualitative study.
Q34162026Impact of pharmacist interventions on patients' adherence to antidepressants and patient-reported outcomes: a systematic review
Q57688816Pharmacist services for non-hospitalised patients
Q42011793Risk factors for drug nonadherence in antidepressant-treated patients and implications of pharmacist adherence instructions for adherence improvement
Q58114372Role and impact of pharmacists in Spain: a scoping review
Q50436405[Impact of pharmaceutical intervention in preventing relapses in depression in Primary Care].

Search more.